These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 3257251)

  • 1. Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells.
    Vujanovic NL; Herberman RB; Maghazachi AA; Hiserodt JC
    J Exp Med; 1988 Jan; 167(1):15-29. PubMed ID: 3257251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
    Schwarz RE; Vujanovic NL; Hiserodt JC
    Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB; Itoh K; Balch CM
    J Immunol; 1987 Feb; 138(4):1068-73. PubMed ID: 3100627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of T cells on the expression of lymphokine-activated killer cell activity and in vivo tissue distribution.
    Maghazachi AA; Goldfarb RH; Herberman RB
    J Immunol; 1988 Dec; 141(11):4039-46. PubMed ID: 2846699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
    Schwarz RE; Hiserodt JC
    J Immunol; 1988 Nov; 141(10):3318-23. PubMed ID: 3263421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemo-immunotherapy: kinetics of in vivo and in vitro generation of natural killer cells and lymphokine-activated killer cells in the rat.
    Stewart LS; Sewell HF; Thomson AW
    Clin Exp Immunol; 1990 Mar; 79(3):416-23. PubMed ID: 2317946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells.
    Sarneva M; Vujanovic NL; Van den Brink MR; Herberman RB; Hiserodt JC
    Cell Immunol; 1989 Feb; 118(2):448-57. PubMed ID: 2910504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precursor phenotype of lymphokine-activated killer cells in the mouse.
    Salup RR; Mathieson BJ; Wiltrout RH
    J Immunol; 1987 Jun; 138(11):3635-9. PubMed ID: 3108370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation and characterization of purified adherent lymphokine-activated killer cells in mice.
    Gunji Y; Vujanovic NL; Hiserodt JC; Herberman RB; Gorelik E
    J Immunol; 1989 Mar; 142(5):1748-54. PubMed ID: 2783950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
    McMannis JD; Fisher RI; Creekmore SP; Braun DP; Harris JE; Ellis TM
    J Immunol; 1988 Feb; 140(4):1335-40. PubMed ID: 3257776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures.
    van den Brink MR; Boggs SS; Herberman RB; Hiserodt JC
    J Exp Med; 1990 Jul; 172(1):303-13. PubMed ID: 2358779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel 120-kD surface antigen expressed by a subset of human lymphocytes. Evidence that lymphokine-activated killer cells express this molecule and use it in their effector function.
    Zocchi MR; Bottino C; Ferrini S; Moretta L; Moretta A
    J Exp Med; 1987 Aug; 166(2):319-26. PubMed ID: 3598463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man.
    Melder RJ; Rosenfeld CS; Herberman RB; Whiteside TL
    Cancer Immunol Immunother; 1989; 29(1):67-73. PubMed ID: 2785002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.